Empagliflozin improves renal outcomes in patients with or without heart failure at baseline - insights from the EMPA-REG OUTCOME trial
28 May 2018 (14:45 - 14:51)
Organised by:
About the speaker

Baylor Scott & White Health, Dallas (United States of America)
14 More presentations in this session

Doctor J. AGOSTINHO (Lisbon, PT)

Doctor P. Martens (Genk, BE)
Access the full session
The Event
Heart Failure 2018
28 May 2018
14:45 CET





